Management of toxicities of immune checkpoint inhibitors
Author:
Publisher
Elsevier BV
Subject
Radiology Nuclear Medicine and imaging,Oncology,General Medicine
Reference91 articles.
1. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors;Curran;Proc Natl Acad Sci USA,2010
2. Improved survival with ipilimumab in patients with metastatic melanoma;Hodi;N Engl J Med,2010
3. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial;Kwon;Lancet Oncol,2014
4. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial;Eggermont;Lancet Oncol,2015
5. Pembrolizumab versus ipilimumab in advanced melanoma;Robert;N Engl J Med,2015
Cited by 677 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Recombinant Newcastle disease viruses expressing immunological checkpoint inhibitors induce a pro-inflammatory state and enhance tumor-specific immune responses in two murine models of cancer;Frontiers in Microbiology;2024-01-24
2. Cardiac magnetic resonance‐based layer‐specific strain in immune checkpoint inhibitor‐associated myocarditis;ESC Heart Failure;2024-01-19
3. Adrenal crisis mainly manifested as recurrent syncope secondary to tislelizumab: a case report and literature review;Frontiers in Immunology;2024-01-16
4. The efficacy of immune checkpoint inhibitors therapy versus chemotherapy in the treatment of advanced and metastatic urothelial carcinoma: a meta-analysis;Journal of Cancer Research and Clinical Oncology;2024-01-03
5. Targeted Therapy and Immunotherapy for Advanced Malignant Conjunctival Tumors: Systematic Review;Ophthalmic Plastic & Reconstructive Surgery;2024-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3